US2013130990A1PendingUtilityA1

Use of spink6 gene and its encoded protein for the preparation of an anti-tumor drug

58
Assignee: HUANG QINGSHANPriority: Oct 12, 2009Filed: Oct 12, 2009Published: May 23, 2013
Est. expiryOct 12, 2029(~3.2 yrs left)· nominal 20-yr term from priority
Inventors:Qingshan HuangWei WangJinjiang HuangHairong LuGuodong Li
C07K 14/8135A61K 38/00A61K 38/57A61P 35/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes use of spink6 gene and the encoded protein in the manufacture of an anti-tumor drug. spink6 gene has a nucleotide sequence designated as SEQ ID NO:1, and the protein encoded by spink6 gene has an amino acid sequence designated as SEQ ID NO:2. The protein encoded by spink6 gene and its derivatives can be used as potential drugs for treatment of human diseases caused by dysregulation of the cell cycle control, such as various malignant tumors, cell abnormal proliferation, and the like.

Claims

exact text as granted — not AI-modified
1 .- 6 . (canceled) 
     
     
         7 . A method for manufacturing an anti-tumor composition, comprising using the spink6 gene, wherein the gene has a nucleotide sequence designated as SEQ ID NO: 1. 
     
     
         8 . The method of  claim 7 , wherein the spink6 gene further comprises a sequence of 69 nucleotides encoding a signal peptide of 23 amino acids at 5′ end of the nucleotide sequence designated as SEQ ID NO: 1, and has a nucleotide sequence designated as SEQ ID NO: 3, and that the protein encoded by the gene further comprises a signal peptide of 23 amino acids at N-terminus of the amino acid sequence designated as SEQ ID NO: 2, and has an amino acid sequence designated as SEQ ID NO: 4. 
     
     
         9 . The method of  claim 7 , wherein the anti-tumor composition is a pharmaceutical composition comprising the amino acid sequence designated as SEQ ID NO: 2. 
     
     
         10 . The method of  claim 7 , wherein the anti-tumor composition comprises a recombinant gene therapy vector. 
     
     
         11 . The method of  claim 8 , wherein the anti-tumor composition is a pharmaceutical composition comprising the amino acid sequence designated as SEQ ID NO: 4. 
     
     
         12 . The method of  claim 8 , wherein the anti-tumor composition comprises a recombinant gene therapy vector comprising the nucleotide sequence designated as SEQ ID NO: 3. 
     
     
         13 . A method for manufacturing an anti-tumor composition, comprising using a protein encoded by the spink6 gene, wherein the spink6 gene has a nucleotide sequence designated as SEQ ID NO: 1. 
     
     
         14 . The method of  claim 13 , wherein the spink6 gene further comprises a sequence of 69 nucleotides encoding a signal peptide of 23 amino acids at 5′ end of the nucleotide sequence designated as SEQ ID NO:1, and has a nucleotide sequence designated as SEQ ID NO:3, and that the protein encoded by the gene further comprises a signal peptide of 23 amino acids at N-terminus of the amino acid sequence designated as SEQ ID NO:2, and has an amino acid sequence designated as SEQ ID NO:4. 
     
     
         15 . The method of  claim 13 , wherein the anti-tumor composition is a pharmaceutical composition comprising the amino sequence designated as SEQ ID NO: 2. 
     
     
         16 . The method of  claim 7 , wherein the protein is expressed as part of a recombinant gene therapy vector. 
     
     
         17 . The method of  claim 16 , wherein the recombinant gene therapy vector comprises the nucleotide sequence designated as nucleotide sequence designated as SEQ ID NO: 3. 
     
     
         18 . A pharmaceutical composition, comprising a protein encoded by the spink6 gene having the nucleotide sequence designated as SEQ ID NO: 1. 
     
     
         19 . The composition of  claim 18 , wherein the protein comprises an amino acid sequence designated as SEQ ID NO: 4. 
     
     
         20 . The composition of  claim 18 , wherein the spink6 gene further comprises a sequence of 69 nucleotides encoding a signal peptide of 23 amino acids at 5′ end of the nucleotide sequence designated as SEQ ID NO: 1, and has a nucleotide sequence designated as SEQ ID NO: 3, and that the protein encoded by the gene further comprises a signal peptide of 23 amino acids at N-terminus of the amino acid sequence designated as SEQ ID NO: 2, and has an amino acid sequence designated as SEQ ID NO: 4. 
     
     
         21 . The composition of  claim 18 , wherein the protein comprises the amino acid sequence designated as SEQ ID NO: 2. 
     
     
         22 . The composition of  claim 21 , wherein the protein is expresses as part of a recombinant gene therapy vector. 
     
     
         23 . The composition of  claim 18 , wherein the protein is expressed as part of a recombinant gene therapy vector. 
     
     
         24 . The composition of  claim 23 , wherein the recombinant gene therapy vector comprises the nucleotide sequence designated as SEQ ID NO: 3. 
     
     
         25 . The composition of  claim 22 , wherein the recombinant gene therapy vector comprises the nucleotide sequence designated as SEQ ID NO: 3. 
     
     
         26 . The composition of  claim 18 , wherein the pharmaceutical composition is an anti-tumor composition.

Join the waitlist — get patent alerts

Track US2013130990A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.